Does clarithromycin resistance affect how doctors treat a Peptic Ulcer infection?

Clarithromycin resistance does change how doctors treat H. pylori, the bacterium that causes most peptic ulcers. Clarithromycin is an antibiotic long used in standard triple therapy, one of the classic first-line treatments for H. pylori. When the bacterium resists this drug, that regimen works less well, so guidelines and experts recommend different combinations. In short: yes, resistance matters, and it pushes doctors toward other regimens.

What the research says

Resistance to clarithromycin is now common. A review of H. pylori eradication evidence reports that clarithromycin resistance exceeds 15% to 20% in most regions, which lowers the effectiveness of standard triple therapy ³. A systematic review and meta-analysis across Asia found that clarithromycin resistance is mainly driven by specific genetic mutations (A2142G/A2143G) and occurs in roughly 19% to 34% of cases ⁴. A 2025 regional consensus from the Middle East also notes that rising resistance to antibiotics including macrolides (the drug class that includes clarithromycin) is a major challenge, and that clarithromycin resistance reduces the effectiveness of standard triple therapy and leads to more treatment failures ⁹.

What to ask your doctor

• Is clarithromycin resistance common in my region, and does that affect which regimen you would choose for me?
• Would a bismuth quadruple or concomitant regimen be a better first choice than standard triple therapy in my case?
• Should I have susceptibility testing (to check which antibiotics the infection resists) before starting treatment?
• What are the pros and cons of susceptibility-guided therapy versus starting an empirical regimen?
• If the first treatment does not work, what second-line options would you consider?